Skip to content
Open access · CC-BY via OpenAlex

Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial

Mijra Koning, Artemiy Kovynev, Marcos F. Fondevila, Eliza J. M. Ruhé, Michiel C. Mommersteeg, Christian R. B. Ramakers, Barbara A. Hutten, Bart J. Verwer, Marije S. Vlug, Teaco Kuiper, Maarten W. Van Den Berg, Anne Vrieze, Maurice B. Bizino, Annewieke W. van den Beld, Luuk Berk

Nature Metabolism · 2026

Abstract

Cellular senescence(definition) plays an important role in hepatic inflammation and fibrosis1–3. However, whether senescence represents a potential therapeutic target in humans with metabolic dysfunction-associated steatohepatitis (MASH) remains unexplored. Here we report the results of a phase-2, double-blind, randomized, placebo-controlled trial of intermittent senolytic therapy with dasatinib plus quercetin (D + Q) in participants with fibrotic MASH. Thirty-one participants (median age 56 years; 76% male; 58% with type 2 diabetes) were randomized (1:1) to receive D + Q (dasatinib 100 mg per day plus quercetin 1,000 mg per day) or placebo for three consecutive days per week over 3 weeks, repeated across three 7-week cycles. The primary endpoint, ≥1 stage fibrosis improvement without MASH worsening on paired liver biopsies, is achieved in 47% of D + Q-treated participants versus 7% with placebo (P = 0.02). MASH resolution occurs more frequently with D + Q than placebo (53% versus 7%; P = 0.02), with a greater reduction in NAFLD Activity Score (−1.43 ± 1.22 versus −0.39 ± 0.77; P = 0.012). Single-nucleus RNA sequencing demonstrates decreased senescence and fibrotic gene signatures and reduced fibrogenic cell populations in the D + Q group. Although adverse events are more frequent in the D + Q group (82% versus 43%), these are all self-limiting. Overall, this proof-of-principle trial supports the need for future trials of senolytic therapy in fibrotic MASH. ClinicalTrials.gov identifier: NCT05506488 . In a double-blind, placebo-controlled trial, intermittent dasatinib and quercetin treatment over 21 weeks improves liver fibrosis in patients with MASH, as shown by paired liver biopsies, and reduces senescence and fibrotic gene signatures, as demonstrated by single-nucleus transcriptomics.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1038/s42255-026-01643-4
Canonical
link ↗
Fetched
2026-10-30 MST

Cite this

APA
Koning, M., Kovynev, A., Fondevila, M.F., Ruhé, E.J.M., Mommersteeg, M.C., Ramakers, C.R.B., Hutten, B.A., Verwer, B.J., Vlug, M.S., Kuiper, T., Berg, M.W.V.D., Vrieze, A., Bizino, M.B., Beld, A.W.V.D., Berk, L., Boerlage, T.C.C., Augustijn, Q.J.J., Brouwer, W.P., Chen, W.J., &amp; Cahen, D.L. (2026). Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial. <em>Nature Metabolism</em>. https://doi.org/10.1038/s42255-026-01643-4
Vancouver
Koning M, Kovynev A, Fondevila MF, Ruhé EJM, Mommersteeg MC, Ramakers CRB, et al. Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial. Nature Metabolism. 2026. doi:10.1038/s42255-026-01643-4.
BibTeX
@article{mijra2026Senoly, title = {Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial}, author = {Mijra Koning and Artemiy Kovynev and Marcos F. Fondevila and Eliza J. M. Ruhé and Michiel C. Mommersteeg and Christian R. B. Ramakers and Barbara A. Hutten and Bart J. Verwer and Marije S. Vlug and Teaco Kuiper and Maarten W. Van Den Berg and Anne Vrieze and Maurice B. Bizino and Annewieke W. van den Beld and Luuk Berk and Thomas C. C. Boerlage and Quinten J. J. Augustijn and Willem Pieter Brouwer and Weena J. Chen and Djuna L. Cahen and Robert C. Verdonk and Wouter J. de Jonge and Sandjai Ramsoekh and Michail Doukas and Sanne Vermorgen}, journal = {Nature Metabolism}, year = {2026}, doi = {10.1038/s42255-026-01643-4}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings